Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the very first-line procedure of CML-CP. Five hundred and nineteen sufferers with recently diagnosed CML-CP have been randomly assigned to get dasatinib in a dose of 100 mg as soon as each day (259 people) https://combretastatina432209.csublogs.com/34989820/getting-my-xmu-mp-1-to-work